1962 related articles for article (PubMed ID: 29306329)
1. Gene-expression signature regulated by the KEAP1-NRF2-CUL3 axis is associated with a poor prognosis in head and neck squamous cell cancer.
Namani A; Matiur Rahaman M; Chen M; Tang X
BMC Cancer; 2018 Jan; 18(1):46. PubMed ID: 29306329
[TBL] [Abstract][Full Text] [Related]
2. Disruption of KEAP1/CUL3/RBX1 E3-ubiquitin ligase complex components by multiple genetic mechanisms: Association with poor prognosis in head and neck cancer.
Martinez VD; Vucic EA; Thu KL; Pikor LA; Lam S; Lam WL
Head Neck; 2015 May; 37(5):727-34. PubMed ID: 24596130
[TBL] [Abstract][Full Text] [Related]
3. TNFAIP2 confers cisplatin resistance in head and neck squamous cell carcinoma via KEAP1/NRF2 signaling.
Xu T; Yang Y; Chen Z; Wang J; Wang X; Zheng Y; Wang C; Wang Y; Zhu Z; Ding X; Zhou J; Li G; Zhang H; Zhang W; Wu Y; Song X
J Exp Clin Cancer Res; 2023 Aug; 42(1):190. PubMed ID: 37525222
[TBL] [Abstract][Full Text] [Related]
4. Integrated analysis of patients with KEAP1/NFE2L2/CUL3 mutations in lung adenocarcinomas.
Jin X; Zheng Y; Chen Z; Wang F; Bi G; Li M; Liang J; Sui Q; Bian Y; Hu Z; Qiao Y; Xu S
Cancer Med; 2021 Dec; 10(23):8673-8692. PubMed ID: 34617407
[TBL] [Abstract][Full Text] [Related]
5. Dysregulation and Epigenetic Reprogramming of NRF2 Signaling Axis Promote Acquisition of Cisplatin Resistance and Metastasis in Head and Neck Squamous Cell Carcinoma.
Osman AA; Arslan E; Bartels M; Michikawa C; Lindemann A; Tomczak K; Yu W; Sandulache V; Ma W; Shen L; Wang J; Singh AK; Frederick MJ; Spencer ND; Kovacs J; Heffernan T; Symmans WF; Rai K; Myers JN
Clin Cancer Res; 2023 Apr; 29(7):1344-1359. PubMed ID: 36689560
[TBL] [Abstract][Full Text] [Related]
6. An integrative investigation on significant mutations and their down-stream pathways in lung squamous cell carcinoma reveals CUL3/KEAP1/NRF2 relevant subtypes.
Liu Z; Deng M; Wu L; Zhang S
Mol Med; 2020 May; 26(1):48. PubMed ID: 32434476
[TBL] [Abstract][Full Text] [Related]
7. c-MYC-directed NRF2 drives malignant progression of head and neck cancer via glucose-6-phosphate dehydrogenase and transketolase activation.
Tang YC; Hsiao JR; Jiang SS; Chang JY; Chu PY; Liu KJ; Fang HL; Lin LM; Chen HH; Huang YW; Chen YT; Tsai FY; Lin SF; Chuang YJ; Kuo CC
Theranostics; 2021; 11(11):5232-5247. PubMed ID: 33859744
[No Abstract] [Full Text] [Related]
8. Genetic alterations of Keap1 confers chemotherapeutic resistance through functional activation of Nrf2 and Notch pathway in head and neck squamous cell carcinoma.
Islam SS; Qassem K; Islam S; Parag RR; Rahman MZ; Farhat WA; Yeger H; Aboussekhra A; Karakas B; Noman ASM
Cell Death Dis; 2022 Aug; 13(8):696. PubMed ID: 35945195
[TBL] [Abstract][Full Text] [Related]
9. Identification of Potential Biomarkers and Survival Analysis for Head and Neck Squamous Cell Carcinoma Using Bioinformatics Strategy: A Study Based on TCGA and GEO Datasets.
Shen Y; Liu J; Zhang L; Dong S; Zhang J; Liu Y; Zhou H; Dong W
Biomed Res Int; 2019; 2019():7376034. PubMed ID: 31485443
[TBL] [Abstract][Full Text] [Related]
10. Impact of KEAP1/NFE2L2/CUL3 mutations on duration of response to EGFR tyrosine kinase inhibitors in EGFR mutated non-small cell lung cancer.
Hellyer JA; Stehr H; Das M; Padda SK; Ramchandran K; Neal JW; Diehn M; Wakelee HA
Lung Cancer; 2019 Aug; 134():42-45. PubMed ID: 31319993
[TBL] [Abstract][Full Text] [Related]
11. Human papillomavirus-driven repression of NRF2 signalling confers chemo-radio sensitivity and predicts prognosis in head and neck squamous cell carcinoma.
Ramesh PS; Bovilla VR; Swamy VH; Manoli NN; Dasegowda KB; Siddegowda SM; Chandrashekarappa S; Somasundara VM; Kabekkodu SP; Rajesh R; Devegowda D; Thimmulappa RK
Free Radic Biol Med; 2023 Aug; 205():234-243. PubMed ID: 37328018
[TBL] [Abstract][Full Text] [Related]
12. Potential inhibitors of RPS6KB2 and NRF2 in head and neck squamous cell carcinoma.
Madhukar G; Subbarao N
J Biomol Struct Dyn; 2024; 42(4):1875-1900. PubMed ID: 37160694
[TBL] [Abstract][Full Text] [Related]
13. Frequent concerted genetic mechanisms disrupt multiple components of the NRF2 inhibitor KEAP1/CUL3/RBX1 E3-ubiquitin ligase complex in thyroid cancer.
Martinez VD; Vucic EA; Pikor LA; Thu KL; Hubaux R; Lam WL
Mol Cancer; 2013 Oct; 12(1):124. PubMed ID: 24138990
[TBL] [Abstract][Full Text] [Related]
14. NRF2 Pathway Activation and Adjuvant Chemotherapy Benefit in Lung Squamous Cell Carcinoma.
Cescon DW; She D; Sakashita S; Zhu CQ; Pintilie M; Shepherd FA; Tsao MS
Clin Cancer Res; 2015 Jun; 21(11):2499-505. PubMed ID: 25739673
[TBL] [Abstract][Full Text] [Related]
15. Downregulation of SELENBP1 enhances oral squamous cell carcinoma chemoresistance through KEAP1-NRF2 signaling.
Zeng H; Zhao X; Tang C
Cancer Chemother Pharmacol; 2021 Aug; 88(2):223-233. PubMed ID: 33907880
[TBL] [Abstract][Full Text] [Related]
16. Lower DSC1 expression is related to the poor differentiation and prognosis of head and neck squamous cell carcinoma (HNSCC).
Wang Y; Chen C; Wang X; Jin F; Liu Y; Liu H; Li T; Fu J
J Cancer Res Clin Oncol; 2016 Dec; 142(12):2461-2468. PubMed ID: 27601166
[TBL] [Abstract][Full Text] [Related]
17. A prognostic mRNA expression signature of four 16q24.3 genes in radio(chemo)therapy-treated head and neck squamous cell carcinoma (HNSCC).
Wintergerst L; Selmansberger M; Maihoefer C; Schüttrumpf L; Walch A; Wilke C; Pitea A; Woischke C; Baumeister P; Kirchner T; Belka C; Ganswindt U; Zitzelsberger H; Unger K; Hess J
Mol Oncol; 2018 Dec; 12(12):2085-2101. PubMed ID: 30259648
[TBL] [Abstract][Full Text] [Related]
18. GSTM3 deficiency impedes DNA mismatch repair to promote gastric tumorigenesis via CAND1/NRF2-KEAP1 signaling.
Chen T; Jinlin D; Wang F; Yuan Z; Xue J; Lu T; Huang W; Liu Y; Zhang Y
Cancer Lett; 2022 Jul; 538():215692. PubMed ID: 35487311
[TBL] [Abstract][Full Text] [Related]
19.
Akdemir B; Nakajima Y; Inazawa J; Inoue J
Mol Cancer Res; 2017 Nov; 15(11):1570-1578. PubMed ID: 28760781
[TBL] [Abstract][Full Text] [Related]
20. KEAP1/NRF2 signaling pathway mutations in cervical cancer.
Chu XY; Li ZJ; Zheng ZW; Tao YL; Zou FX; Yang XF
Eur Rev Med Pharmacol Sci; 2018 Jul; 22(14):4458-4466. PubMed ID: 30058679
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]